Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries

Cardiovascular Research

Volumn 79, Issue 1, 2008, Pages 161-168

  Hirao, Akiko ^a   Kondo, Kazunao ^a   Takeuchi, Kazuhiko ^a   Inui, Naoki ^a   Umemura, Kazuo ^a   Ohashi, Kyoichi ^b   Watanabe, Hiroshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Endothelium; Prostanoids; Remodeling; Vasoconstricting factor(s)

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLCHOLINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; OZAGREL; POTASSIUM CHLORIDE; PROSTAGLANDIN F2 ALPHA; PROSTANOID; THROMBOXANE A2; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOTHELIUM INJURY; FEMORAL ARTERY; HYPERPOLARIZATION; IRRADIATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; VASCULAR ENDOTHELIUM; VASODILATATION; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; BIOLOGICAL FACTORS; CYCLOOXYGENASE INHIBITORS; DINOPROST; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; MALE; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITROBENZENES; PROSTAGLANDIN H2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 45849137405     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn111     Document Type: Article

References (41)

1. Schwartz SM, Benditt EP. Aortic endothelial cell replication. I. Effects of age and hypertension in the rat. Circ Res 1977;41:248-255.
2. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 2007;27:266-274.
3. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993;73:792-796.
4. Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest 1975;32:339-351.
5. Shimokawa H, Flavahan NA, Vanhoutte PM. Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. Circ Res 1989;65:740-753.
6. Kikuchi S, Umemura K, Kondo K, Saniabadi AR, Nakashima M. Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening. Arterioscler Thromb Vasc Biol 1998;18:1069-1078.
7. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993;7:308-316.
8. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-752.
9. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-59.
10. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 2006;26:1215-1225.
11. Chen G, Suzuki H. Some electrical properties of the endothelium-dependent hyperpolarization recorded from rat arterial smooth muscle cells. J Physiol 1989;410:91-106.
12. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998;95:13313-13318.
13. Patrono C. Thromboxane synthesis inhibitors and receptor antagonists. Thromb Res Suppl 1990;11:15-23.
14. Hunt JA, Merritt JE, MacDermot J, Keen M. Characterization of the thromboxane receptor mediating prostacyclin release from cultured endothelial cells. Biochem Pharmacol 1992;43:1747-1752.
15. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther 1999;290:1278-1284.
16. Halushka PV, Mais DE, Mayeux PR, Morinelli TA. Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharmacol Toxicol 1989;29:213-239.
17. Camacho M, Lopez-Belmonte J, Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res 1998;83:353-365.
18. Kurahashi K, Nishihashi T, Trandafir CC, Wang AM, Murakami S, Ji X. Diversity of endothelium-derived vasocontracting factors-arachidonic acid metabolites. Acta Pharmacol Sin 2003;24:1065-1069.
19. Alfranca A, Iniguez MA, Fresno M, Redondo JM. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res 2006;70:446-456.
20. Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D, Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther 2002;300:393-398.
21. Yamada M, Numaguchi Y, Okumura K, Harada M, Naruse K, Matsui H et al. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler Thromb Vasc Biol 2002;22:256-262.
22. Diederich D, Yang ZH, Buhler FR, Luscher TF. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990;258:H445-H451.
23. Kaiser L, Spickard RC, Olivier NB. Heart failure depresses endothelium-dependent responses in canine femoral artery. Am J Physiol 1989;256:H962-H967.
24. Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S et al. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005;312:945-953.
25. Huang A, Sun D, Smith CJ, Connetta JA, Shesely EG, Koller A et al. In eNOS knockout mice skeletal muscle arteriolar dilation to acetylcholine is mediated by EDHF. Am J Physiol 2000;278:H762-H768.
26. Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 2005;111:796-803.
27. Malmsjö M, Bergdahl A, Zhao XH, Sun XY, Hedner T, Edvinsson L et al. Enhanced acetylcholine and P2Y-receptor stimulated vascular EDHF-dilatation in congestive heart failure. Cardiovasc Res 1999;43:200-209.
28. Marrelli SP, Khorovets A, Johnson TD, Childres WF, Bryan RM Jr. P2 purinoceptor-mediated dilations in the rat middle cerebral artery after ischemia-reperfusion. Am J Physiol 1999;276:H33-H41.
29. Lacza Z, Dezsi L, Kaldi K, Horvath EM, Sandor P, Benyo Z. Prostacyclin-mediated compensatory mechanism in the coronary circulation during acute NO synthase blockade. Life Sciences 2003;73:1141-1149.
30. Bolz SS, Pohl U. Indomethacin enhances endothelial NO release-evidence for a role of PGI2 in the autocrine control of calcium-dependent autacoid production. Cardiovasc Res 1997;36:437-444.
31. Takeuchi K, Watanabe H, Tran QK, Ozeki M, Sumi D, Hayashi Tet al. Nitric oxide: inhibitory effects on endothelial cell calcium signaling, prostaglandin I2 production and nitric oxide synthase expression. Cardiovasc Res 2004;62:194-201.
32. Lippolis L, Sorrentino R, Popolo A, Maffia P, Nasti C, d'Emmanuele di Villa Bianca R et al. Time course of vascular reactivity to contracting and relaxing agents after endothelial denudation by balloon angioplasty in rat carotid artery. Atherosclerosis 2003;171:171-179.
33. Paravicini TM, Gulluyan LM, Dusting GJ, Drummond GR. Increased NADPH oxidase activity, gp91phox expression, and endothelium-dependent vasorelaxation during neointima formation in rabbits. Circ Res 2002;91:54-61.
34. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L et al. Balloon angioplasty Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-112.
35. Labinaz M, Pels K, Hoffert C, Aggarwal S, O'Brien ER. Time course and importance of neoadventitial formation in arterial remodeling following balloon angioplasty of porcine coronary arteries. Cardiovasc Res 1999;41:255-266.
36. Zeiher AM, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-1992.
37. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-933.
38. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 non-insulin-dependent diabetes mellitus. Diabetologia 1992;35:771-776.
39. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993;88:55-61.
40. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33-65.
41. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-720.